In conclusion, the data reported in the present article demonstrate that the inhibition of CXCR1/2 through DF2755A can be a potential therapeutic approach for the treatment of not only inflammatory painful conditions but also neuropathic ones and in particular peripheral neuropathy in non-Hunner IC/BPS. This evidence concerns the gene CXCR1 and peripheral neuropathy.